Home CompaniesAstraZeneca France HAS Approves AstraZeneca’s Evusheld for High-Risk Covid Cases

France HAS Approves AstraZeneca’s Evusheld for High-Risk Covid Cases

by admin
0 comment
Pharma, HAS, France, Antibody , Therapy, Evusheld, AstraZeneca , Corona, Virus, Dose, Vaccine

Summary –

French health authorities have approved the use of an antibody treatment made by AstraZeneca for high-risk people who show resistance to vaccines against coronavirus.

On Friday night, independent public health body HAS (Haute Autorité de santé) announced “a greenlight for the preventive use of Evusheld… for patients with a very high-risk of contracting a severe form of Covid-19”.

Evusheld, developed by the British-Swedish pharma company, this week received emergency-use authorisation in the United States for adults and children aged 12 and above.

Pharma, HAS, France, Antibody , Therapy, Evusheld, AstraZeneca , Corona, Virus, Dose, Vaccine

France HAS Aprroves AZ Evusheld

The French approval is for adults only.

Evusheld, which is made from a combination of two monoclonal antibodies, is administered in two injections.

Monoclonal antibodies — which recognise a specific molecule of the target virus or bacteria — are synthetic versions of natural antibodies.

Unlike most other Covid treatments, which are given to already hospitalised patients to prevent serious illness, Evusheld is for people who have yet to be infected but may not mount an adequate immune response.

HAS  warned of cardiovascular risks identified during clinical trials and recommended the drug not be given to cases with two or more risk factors such as diabetes and obesity.

For more Information: Sign in Websites for Agrochemical & Pharmaceutical Databases:

Website : https://www.chemrobotics.com/ (Agrochemical Databases)

Website : https://chemroboticspharma.com/  (Pharmaceutical Databases)

You may also like

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Our Company

Lorem ipsum dolor sit amet, consect etur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis.

ChemRobotics Times

Subscribe my Newsletter for new blog posts, tips & new photos. Let's stay updated!

Laest News

@2021 – All Right Reserved. Designed and Developed by Ample eBusiness

WP2Social Auto Publish Powered By : XYZScripts.com